FreeTheAI

Iambic Therapeutics Sets Initial Public Offering Price at $16

NeutralMedium impact

Iambic Therapeutics, Inc. (IAM) set the purchase price for its initial public stock sale at $16.00 per share, making 9,375,000 common shares available to investors. Through this issuance, the firm anticipates collecting $150.0 million in total revenue prior to subtracting underwriting allowances and listing costs. Financial institutions managing the deal also received a 30-day option allowing them to purchase as many as 1,406,250 additional shares at the established price.

The fresh funding will support the clinical-stage biotech enterprise as it expands its proprietary technology platform, which combines artificial intelligence with laboratory automation to discover and engineer therapeutics. The system has already produced IAM1363, a drug candidate currently undergoing human testing after reaching trials in roughly two years.

Public trading for the company's equity commences October 15, 2026, on the Nasdaq Global Select Market with the ticker symbol IAM. Final settlement for the stock transaction is set for October 16, 2026, assuming standard terms are fulfilled. The underwriting group leading the offering includes J.P. Morgan, Jefferies, BofA Securities, and Citigroup.

Key points

  • Iambic Therapeutics priced 9,375,000 shares in its IPO at $16.00 per share.
  • The company anticipates gross proceeds of $150.0 million before fee deductions.
  • Underwriters hold an option to buy up to 1,406,250 extra shares within 30 days.
  • Shares begin trading October 15, 2026, on the Nasdaq Global Select Market as IAM.
  • The transaction is targeted to close on October 16, 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

At what price did Iambic Therapeutics list its IPO?

Iambic Therapeutics set its initial public offering price at $16.00 per share, offering 9,375,000 common shares.

What ticker symbol will Iambic Therapeutics use on Nasdaq?

The company will list its stock on the Nasdaq Global Select Market under the ticker symbol IAM starting October 15, 2026.

How much money is Iambic Therapeutics raising from the IPO?

The offering is expected to bring in $150.0 million in gross proceeds before paying underwriting discounts and fees.